GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Shares Outstanding (Basic Average)

Implantica AG (OSTO:IMP A SDB) Shares Outstanding (Basic Average) : 0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Implantica AG's average basic shares outstanding for the quarter that ended in . 20 was 0.00 Mil.


Implantica AG Shares Outstanding (Basic Average) Historical Data

The historical data trend for Implantica AG's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Shares Outstanding (Basic Average) Chart

Implantica AG Annual Data
Trend
Shares Outstanding (Basic Average)

Implantica AG Semi-Annual Data
Shares Outstanding (Basic Average)

Implantica AG Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Implantica AG  (OSTO:IMP A SDB) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Implantica AG Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Implantica AG's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines